Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy
NCT00183950 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2014-05-22
Summary
This study is for patients with non-hodgkin's lymphoma or chronic lymphocytic leukemia, which has failed to shrink or has returned after previous treatment with chemotherapy. The purpose of this study is to find out whether patients with these types of cancer will have their tumor shrunk after treatment with a drug called Noscapine. The second purpose is to see what are the side effects of this drug. This drug is being used as an over-the-counter cough suppressor in Europe and Japan, but has also shown to be effective against cancer.
Conditions
- Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia
Interventions
- DRUG
-
Noscapine
Sponsors & Collaborators
-
University of Southern California
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-03-31
- Primary Completion
- 2006-12-31
- Completion
- 2006-12-31
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
NCT02561273 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00002745 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
NCT00695448 ·Status: TERMINATED ·Phase: PHASE1
-
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
NCT02095574 ·Status: WITHDRAWN ·Phase: PHASE1
-
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
NCT00574496 ·Status: COMPLETED ·Phase: PHASE2
-
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
NCT01055314 ·Status: COMPLETED ·Phase: PHASE2
-
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT02420795 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282 ·Status: RECRUITING ·Phase: PHASE1
-
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00452127 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00550615 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
NCT00002501 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
NCT04657224 ·Status: COMPLETED ·Phase: PHASE1
-
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
NCT00005982 ·Status: TERMINATED ·Phase: PHASE2
-
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
NCT03259503 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT03704714 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
NCT01032148 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
NCT00513188 ·Status: WITHDRAWN ·Phase: NA
-
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
NCT01995669 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT01116154 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
NCT04240704 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05950165 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
506U78 in Treating Patients With Lymphoma
NCT00005080 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
NCT00499239 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
NCT00096460 ·Status: TERMINATED ·Phase: PHASE2/PHASE3